Gilead Sciences agreed to acquire Arcellx for $7.8 billion, or $115 per share in cash, plus a $5-per-share contingent value right. The acquisition strengthens Gilead's oncology portfolio by adding anito-cel, a CAR T-cell therapy for multiple myeloma with promising clinical results. Arcellx shares rose on the news and are trading near their 52-week highs.

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. The investigations concern Arcellx's $115 per share sale to Gilead Sciences, Enhabit's $13.80 per share sale to Kinderhook Industries, and Veris Residential's $19 per share sale to an Affinius Capital-led consortium. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Gilead Sciences announced a definitive agreement to acquire biotechnology company Arcellx for approximately $7.8 billion ($115 per share in cash), representing a 68% premium to Arcellx's 30-day volume-weighted average price. The deal includes a contingent value right of $5 per share if anito-cel, Arcellx's lead CAR-T therapy, reaches $6 billion in cumulative global net sales by end of 2029. The acquisition is expected to close in Q2 2026 and expands Gilead's existing collaboration with Arcellx on the investigational BCMA-directed CAR-T cell therapy for multiple myeloma.

Gilead Sciences announced the acquisition of Arcellx for $115 per share in cash plus a $5 per share contingent value right, totaling $7.8 billion in implied equity value. The deal aims to accelerate development and commercialization of anito-cel, a CAR T-cell therapy for relapsed or refractory multiple myeloma, with FDA approval anticipated by December 2026. The transaction is expected to be accretive to Gilead's earnings per share starting in 2028.

The CAR T-cell therapy market for multiple myeloma is expected to grow significantly by 2034, driven by extensive R&D activities, emerging therapies targeting BCMA, and increasing multiple myeloma incidence rates.

The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

Gilead Sciences reported strong Q4 2024 results, with revenue and earnings beating consensus. The company raised its 2025 outlook and is preparing for the potential launch of lenacapavir for HIV prevention in 2025, which could strengthen its HIV leadership.

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Arcellx (NASDAQ:ACLX) in the last three months. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 4 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.09, a high estimate of $87.00, and a low estimate of $70.00. Observing a 10.7% increase, the current average has risen from the previous average price target of $73.25. Investigating Analyst Ratings: An Elaborate Study In examining recent analyst actions, we gain insights into how financial experts perceive Arcellx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Biren Amin Piper Sandler Announces Overweight $70.00 - Benjamin Burnett Stifel Raises Buy $83.00 $82.00 Cory Kasimov Evercore ISI Group Announces Outperform $85.00 - Emily Bodnar HC Wainwright & Co. Lowers Buy $80.00 $82.00 Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Raises Buy $81.00 $72.00 Benjamin Burnett Stifel Maintains Buy $82.00 - Judah Frommer Morgan Stanley Announces Overweight $81.00 - Asthika Goonewardene Truist Securities Raises Buy $87.00 $57.00 Key Insights: Action Taken: In response ...Full story available on Benzinga.com

During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 10 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 3 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 5 3 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $80.57, a high estimate of $87.00, and a low estimate of $72.00. Witnessing a positive shift, the current average has risen by 20.94% from the previous average price target of $66.62. Breaking Down Analyst Ratings: A Detailed Examination The analysis of recent analyst actions sheds light on the perception of Arcellx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Cory Kasimov Evercore ISI Group Announces Outperform $85.00 - Emily Bodnar HC Wainwright & Co. Lowers Buy $80.00 $82.00 Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Maintains Buy $81.00 - Gil Blum Needham Raises Buy $81.00 $72.00 Benjamin Burnett Stifel Maintains Buy $82.00 - Judah Frommer Morgan Stanley Announces Overweight $81.00 - Asthika Goonewardene Truist Securities Raises Buy $87.00 $57.00 Emily Bodnar HC Wainwright & Co. Raises Buy $82.00 $60.00 John Newman Canaccord Genuity Raises Buy $85.00 $66.00 Carter Gould Barclays Raises Overweight $73.00 $62.00 Gil Blum Needham Raises Buy $72.00 $71.00 Jack Allen Baird Raises Outperform $77.00 $63.00 Key Insights: Action Taken: Analysts adapt their recommendations to ...Full story available on Benzinga.com

Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?